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ABSTRACT
A role for BRCA1 in the direct and indirect regulation
of transcription is well established. However, a com-
prehensive view of the degree to which BRCA1
impacts transcriptional regulation on a genome-
wide level has not been defined. We performed
genome-wide expression profiling and ChIP-chip
analysis, comparison of which revealed that
although BRCA1 depletion results in transcriptional
changes in 1294 genes, only 44 of these are pro-
moter bound by BRCA1. However, 27% of these
transcripts were linked to transcriptional regulation
possibly explaining the large number of indirect
transcriptional changes observed by micro-
array analysis. We show that no specific consensus
sequence exists for BRCA1 DNA binding but rather
demonstrate the presence of a number of known
and novel transcription factor (TF)- binding sites
commonly found on BRCA1 bound promoters.
Co-immunoprecipitations confirmed that BRCA1
interacts with a number of these TFs including
AP2-a, PAX2 and ZF5. Finally, we show that BRCA1
is bound to a subset of promoters of genes that are
not altered by BRCA1 loss, but are transcriptionally
regulated in a BRCA1-dependent manner upon DNA
damage. These data suggest a model, whereby
BRCA1 is present on defined promoters as part of
an inactive complex poised to respond to various
genotoxic stimuli.
INTRODUCTION
One of the major functions of BRCA1 is its role in tran-
scription, ﬁrst proposed upon the discovery of highly
conserved regions of acidic amino acids in its C-terminus,
and later with reporter assays using BRCA1–GAL4 DNA
fusions (1). A physiological role for BRCA1 transcriptional
activity was suggested by the ﬁnding that pathogenic
mutations within the BRCA1 C-terminus abolished
GAL4–BRCA1-mediated transactivation and growth sup-
pression (1,2). Furthermore, BRCA1 co-puriﬁes in a
complex with the RNA Polymerase II holoenzyme via
interaction with RNA helicase A, and transcriptional ac-
tivation by this complex was found to require BRCA1
(3,4). BRCA1 binds DNA directly, prompting the idea
that BRCA1 binds to genetic promoters and, through
interaction with the core transcriptional machinery,
directly affects transcription (1). However, more recent
evidence suggests that BRCA1 does not bind to DNA in
a sequence-speciﬁc manner and that its direct DNA
binding activity may be restricted to branched DNA struc-
tures, consistent with its role in DNA repair (5).
Extensive research has revealed that BRCA1 regulates
transcription in a number of ways. BRCA1 can regulate
signalling pathways that affect transcription factor (TF)
activation. For example, BRCA1 phosphorylation in re-
sponse to DNA damage is required for ATM (Ataxia
Telangiectasia Mutated)-mediated p53 phosphorylation
and activation, regulating the p53-dependent G1/S check-
point (6). Furthermore, BRCA1 binds to ERa and
represses both ligand-dependent and independent ERa
signalling, affecting E2/ERa-dependent transcription
(7,8).
In addition to this ‘indirect’ role in transcriptional regu-
lation, BRCA1 has been identiﬁed on a number of target
gene promoters where it directly inﬂuences gene expres-
sion (9–13). Given BRCA1’s lack of sequence-speciﬁc
DNA binding, BRCA1 is likely to be recruited to pro-
moters by sequence-speciﬁc DNA binding TFs.
Consistent with this, BRCA1 interacts with a large pool
of TFs, many of which recruit BRCA1 to promoters
(14,15). When recruited to promoters, BRCA1 may act
as either a transcriptional co-activator or co-repressor, de-
pendent upon the TF(s) and other accessory factors,
including chromatin remodelling factors, bound at the
speciﬁc promoter.
BRCA1 binds to a number of chromatin remodelling
factors such as HDAC1 and HDAC2, and with the BRG1
and BRD7 subunits of the SWI/SNF complex (13,16,17).
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part of a HAT (Histone Acetyl Transferase) complex
which requires BRCA1 for activation (18). Taken
together, this suggests that BRCA1 plays an accessory
role in transcriptional regulation, modulating the recruit-
ment and activity of various proteins within promoter
bound complexes.
Here, we have used a combination of ChIP-chip and
microarray-based expression proﬁling to provide a
genome-wide overview of the role played by BRCA1 in
transcriptional regulation. We provide evidence to suggest
that BRCA1 is recruited to deﬁned promoters through
interactions with a range of known and novel TFs.
Finally, we suggest that BRCA1’s role in these pre-
assembled complexes appears to be important for medi-
ating transcriptional responses to deﬁned stimuli, such as
ionizing radiation or etoposide treatment.
MATERIALS AND METHODS
Cell lines
MCF7 cells were obtained from the ECACC, Wiltshire,
UK, and routinely maintained as detailed (19).
siRNA transfection
Scrambled control siRNA were obtained from Invitrogen.
BRCA1 siRNAs were obtained from Qiagen; BRCA1 #2:
50CAGGAAATGGCTGAACTAGAA 30, BRCA1 #3:
50ACCATACAGCTTCATAAATAA 30. Oligos were de-
livered to a ﬁnal concentration of 10nM by reverse trans-
fection using RNAiMax (Invitrogen, Paisley, UK)
according to manufacturer’s instructions.
qPCR analysis
A quantity of 2mg of RNA was reverse transcribed using
MMLV (Invitrogen) according to the manufacturer’s in-
structions. The qRT–PCR was performed using primers
speciﬁc to each transcript, or to actin mRNA. All qRT–
PCR primers were designed using the Roche Universal
Probe library (www.roche.com) and obtained from
MWG (S10).
Clonogenic assays
About 1 10
3 MCF-7 cells were seeded into 6-well plates.
After 24h, the cells were exposed to a medium containing
increasing doses of PARP-1 inhibitor (KU0058948). Cell
medium was replenished every 4 days. After 12 days, the
cells were ﬁxed, stained with crystal violet and counted.
Preparation of nuclear extracts and immunoprecipitations
Co-immunoprecipitations of BRCA1 were carried out
from nuclear extracts of 293T HEK cells as described pre-
viously (19). A quantity of 2mg of the monoclonal
antibody Ab-1 (Calbiochem), IgG1 (DAKO, Denmark)
or HA antibody (Santa Cruz) were used.
Western blotting
Nuclear extracts were prepared and quantitated as de-
scribed previously (19). Samples were resolved by SDS–
PAGE and western blotted for BRCA1 (D9); E2F-1
(sc251); AP2-a (sc-81182); Pax 2 (sc133889); Pax 4
(sc-27832) (Santa-Cruz Biotechnology); PPM1D
(WP-401) Bioworld; PDE4DIP (HOOOO9659) stratech;
ZF5 (sab1402396) Millipore; NME1 (5353S) NEB.
Gene expression proﬁling and analysis
RNA labelling and hybridization and analysis was as
detailed in previous study (19).
Chromatin immunoprecipitations
ChIP assays were performed as previously described (19).
Antibodies used for immunoprecipitation were RNA
Polymerase II (CTD4H8, Millipore), BRCA1 (Ab-1;
Calbiochem), HA (sc-805, Santa Cruz) rabbit IgG and
IgG1 (DAKO). Immunoprecipitated DNA was puriﬁed
using QIAquick PCR puriﬁcation kit (Qiagen). Semi-
quantitative and qPCR ampliﬁcation was performed on
the puriﬁed DNA using primers that were designed to spe-
ciﬁc regions of BRCA1 bound peaks identiﬁed from array
analysis (S10). For ChIPs analysed by qPCR, fold en-
crichment was calculated by ﬁrst normalizing to input
qPCR and then normalizing to the same normalized
value calculated for the same ChIP using primers speciﬁc
to a control region  2kp upstream of the S100A7 TSS.
ChIP-chip and analysis
Puriﬁed, immunoprecipitated and total DNA were amp-
liﬁed using LMPCR as directed by NimbleGen protocols
(see http://NimbleGen.com for details). A quantity of 4mg
of immunoprecipiated and total DNA was shipped to
NimbleGen Systems for labelling and array hybridization
on NimbleGen Human ChIP-chip 385K refseq Promoter
array. This array covers 24659 transcripts (2200bp up-
stream tiling, 500bp downstream tiling, probes are
spaced  100bp apart). Analysis and peak identiﬁcation
was performed by Roche NimbleGen. Binding peaks are
detected by searching for 4 or more probes whose signals
are above the speciﬁed cutoff values, ranging from 90% to
15%, using a 500bp sliding window. The cut-off values
are a percentage of a hypothetical maximum, which is the
mean+6 SD. The ratio data are then randomized 20 times
to evaluate the probability of ‘false positives’. Each peak is
then assigned a false discovery rate (FDR) score based on
the number of peaks still exceeding the cut-off values after
20 randomizations. Binding peaks with an FDR  0.2 are
considered strong/true binding regions.
RESULTS
Identiﬁcation of potential BRCA1 regulated genes by
microarray expression proﬁling
To identify transcriptional targets of BRCA1, we
performed microarray expression analysis of BRCA1-
depleted MCF7 cells using a breast tissue enriched expres-
sion array (BrDSA, ALMAC diagnostics). BRCA1 was
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two different BRCA1-targeted siRNA oligos (BRCA1 II
and III, respectively). Control cells were transfected with a
scrambled siRNA oligo. BRCA1 depletion was conﬁrmed
at both the protein and mRNA level prior to array hy-
bridization (Figure 1A and B). Loss of BRCA1 confers
sensitivity to Poly-ADP Ribose Polymerase (PARP) inhib-
ition due to accumulation of unrepaired DNA damage
(20,21). Therefore, we conﬁrmed the functionality of
BRCA1 depletion for both siRNA oligonucleotides by
testing the sensitivity of BRCA1-depleted cells to the
PARP inhibitor KU0058948 (20). Cells treated with
either BRCA1 siRNA oligo were sensitive to PARP inhib-
ition (IC50 3.126 10
 9 M and 2.517 10
 9 M compared
with IC50>1 10
 4 M for scrambled control) conﬁrming
functionality of BRCA1 depletion in these cells (Figure
1C).
BRCA1 differentially expressed gene lists for each siRNA
oligo were generated by comparing either BRCA1 II with
control or BRCA1 III with control, using all 4 samples in
each group. Expression fold change was computed for
each probe in each group and both the fold change and
P-value were used for ﬁltering in order to generate differ-
entially expressed gene lists (fold change 1.7, P 0.05)
(22). Depletion of BRCA1 with either BRCA1 siRNA
oligo resulted in altered expression of  10% of probe
sets on the BrDSA relative to control. In order to gain a
more precise list of differentially expressed genes following
BRCA1 loss, we overlapped the two probe set lists gene-
rated (siRNA II and III which contained 5782 and 4630
BRCA1 regulated probe sets, respectively) to produce a
ﬁnal common list containing 2211 probe sets representing
1294 BRCA1-regulated genes (Figure 1D). Heat map
analysis of these probe sets shows a clear correlation with
BRCA1 loss between the two oligo sets (Figure 1E). Gene
Ontology analysis revealed that loss of BRCA1 leads to
transcriptional regulation of genes involved in multiple cel-
lular processes previously linked to BRCA1 such as cell
cycle arrest, signal transduction, chromatin remodelling
and transcription (Supplementary Figure S1).
Identiﬁcation of direct BRCA1 transcriptional targets
by ChIP-chip analysis
It is evident from expression proﬁling that loss of BRCA1
results in radical changes in transcription proﬁles.
However, it is likely that many of the transcriptional
changes are secondary effects mediated by BRCA1-
dependent regulation of additional transcriptional regula-
tors, such as ERa (23) and/or as a cellular response to
increased genomic instability/cellular stress caused by
BRCA1 loss. Therefore, in order to identify direct tran-
scriptional targets of BRCA1, we performed ChIP-chip,
using the well-characterized NimbleGen HG18 promoter
array. Three independent BRCA1 ChIP assays were per-
formed from MCF7 cells. Prior to hybridization to pro-
moter arrays, we conﬁrmed efﬁcient immunoprecipitation
of BRCA1 by western blot analysis (Figure 2A).
Speciﬁcity of the BRCA1 ChIP was analysed by PCR
using primers speciﬁc for S100A7 and ESR1 promoters,
which are known to be directly bound and regulated by
BRCA1 (9,10) (Figure 2B). We also performed PCR using
primers upstream of S100A7 and ESR1 transcription start
sites (TSS) to ensure that the BRCA1 antibody was not
precipitating DNA non-speciﬁcally (Figure 2B). ChIP-
chip data was analysed using NimbleScan. Perl script was
generated in order to identify the overlap of binding sites
between at least two biological replicates with an enrich-
ment score >1 and FDR<0.2. Using this approach, we
identiﬁed 980 BRCA1 bound peaks (Supplementary
Figure S2). BRCA1 binding peaks from ChIP-chip data
were visualized using Integrative Genomic Viewer (IGV)
(Broad Institute, MIT), examples of peaks observed
for S100A7 and ESR1 are shown (Figure 2C and
Supplementary Figure S3).
We initially analysed the genomic distribution of
BRCA1 bound peaks and determined that BRCA1
binds uniformly to all chromosomes within the genome
(Figure 2D). Uniform binding of BRCA1 was conﬁrmed
using linear regression and correlation analysis, which re-
vealed no statistically signiﬁcant BRCA1 binding clusters
(P=0.790), indicating that BRCA1 is a genome-wide TF.
Given that BRCA1 binds genetic promoters, we per-
formed a search for conserved regions/sequences within all
980 BRCA1 bound peaks using DeNovo sequence analysis
software (24,25). We could not identify any conserved
DNA sequences common to the BRCA1 bound regions,
suggesting that BRCA1 is binding to different genetic pro-
moters through interaction with a range of DNA binding
TFs. Cis-regulatory Element Annotation System (CEAS
http://liulab.dfci.harvard.edu/CEAS/) analysis conﬁrmed
the majority of BRCA1 bound peaks to be within the
proximal promoter region ( 1000bp) of genes (26)
(Figure 2E and F), suggesting that BRCA1 is playing an
important role in the direct transcriptional regulation of
the genes identiﬁed. Additionally, CEAS analysis identi-
ﬁed a number of binding sites of known BRCA1 interact-
ing TFs such as Sp1, ATF and CREB (Supplementary
Figure S4) (27,28).
Since BRCA1 was identiﬁed as bound primarily to
proximal promoter regions ( 53% of binding sites) and
given the difﬁculty of accurately distinguishing uncon-
ﬁrmed enhancer regions, we performed a consensus TF-
binding motif search to BRCA1 bound peaks found
within 500bp of known TSSs. This identiﬁed a number
of potential BRCA1 recruiting TFs including some previ-
ously described BRCA1 interacting/recruiting TFs and the
well characterized BRCA1 interacting c-Myc/Max
complex (29,30) (Figure 2G).
Comparison of Chip-chip and microarray datasets
In order to identify genes that were differentially expressed
upon BRCA1 loss and demonstrated BRCA1 promoter
binding, we compared the ChIP-chip and microarray
data. Differentially expressed genes from the BrDSA
situated adjacent to shared binding peaks from BRCA1
ChIP-chip were matched using gene accession number. Of
the 24695 transcripts covered on the ChIP-chip array
15898 of their associated genes are also covered on the
BrDSA (Supplementary Figure S5). Therefore, as not all
of the transcripts identiﬁed within the promoter array were
9538 Nucleic Acids Research, 2011,Vol.39, No. 22present on the BrDSA expression array, we discounted the
BRCA1 bound peaks that did not have corresponding
gene probes on the BrDSA (Supplementary Figure S5).
The number of BRCA1 bound ChIP-chip targets for com-
parison was therefore, reduced from 980 to 890. From 890
possible peaks (608 genes), we identiﬁed 65 probe sets (47
genes), which were common to both data sets (Figure 3A
and Supplementary Figure S6). This was intriguing for
two reasons; primarily, it suggested that a large propor-
tion of BRCA1-regulated genes identiﬁed from BrDSA
expression proﬁling were modulated indirectly by
BRCA1 loss. However, it also suggested that BRCA1
complexes found at the majority of promoters in unper-
turbed cells were non-functional in terms of gene expres-
sion modulation.
Characterization of direct BRCA1 transcriptional
targets in unperturbed cells
To examine the ﬁrst of these observations we sought to
better understand the small subset of genes that were
Figure 1. Microarray-based expression proﬁling. (A) Western blot and (B) qRT–PCR conﬁrming siRNA inhibition of BRCA1 levels with two
BRCA1 siRNA oligos (II and III) in MCF7 cells when compared with scrambled control (SCR). (C) Clonogenic assay demonstrating sensitivity to
PARP-1 inhibitor (KU0058948) of cells treated with scrambled control (SCR) or BRCA1-speciﬁc siRNA oligos II or III. (D) Venn diagram of the
probe set intersect after gene expression array analysis for each BRCA1 siRNA oligo; oligo II (left circle) or oligo III (right circle), in MCF7 cells.
There are 2211 shared probe sets which correlate to 1294 genes. (E) Heat map from two-way hierarchical clustering analysis based on the 2211
common shared probe sets and 12 samples (4 per siRNA oligo).
Nucleic Acids Research, 2011,Vol.39, No. 22 9539Figure 2. ChIP-chip expression proﬁling. (A) Western blot conﬁrming immunoprecipitation of BRCA1 from MCF7 cells during ChIP with
BRCA1-speciﬁc antibody AB1. (B) qRT–PCR for ChIP assays conﬁrming BRCA1 recruitment to promoters of S100A7 and ESR1. Amounts of
immunoprecipitated DNA were normalized to inputs and reported relative to the amount obtained at a non-speciﬁc control region. Isotope matched
IgG and HA antibodies were used as internal controls for each immunoprecipitation. (C) Binding peaks of the three independent BRCA1 ChIP
samples from ChIP-chip data in MCF7 cells are shown for S100A7 and ESR1 probe sets. (D) Histogram demonstrating distribution of BRCA1
binding across the genome. The frequency of BRCA1 binding across chromosomes was calculated by dividing the number of probe sets per
chromosome (data provided by NimbleGen) by the number of probe sets bound by BRCA1 with FDR <0.2. (E) Histogram demonstrating
relative BRCA1 bound peak location with respect to chromosome region. (F) Chart demonstrating the signiﬁcance of enrichment of the top 20
consensus TF binding motifs identiﬁed within peak coordinates of BRCA1 bound promoters where peak coordinates were within 500bp of the TSS.
Signiﬁcance of enrichment represents those motifs which have hits which are signiﬁcantly enriched in the ChIP regions with >2-fold change over hits
within the genomic regions and binomial test P<1E-10.
9540 Nucleic Acids Research, 2011,Vol.39, No. 22bound by BRCA1 and differentially regulated following
loss of BRCA1 in unperturbed cells. Heat map analysis
of the 47 genes revealed that 54% of genes were up-
regulated versus 40% downregulated conﬁrming BRCA1
acts as both an activator and repressor (Figure 3B).
The expression of three of the genes identiﬁed (6%) were
regulated differentially between the two oligo sets and
were therefore, excluded from analysis. To identify
whether the remaining 44 genes were involved in
common cellular processes, we performed gene ontology
Figure 3. Characterization of direct BRCA1 transcriptional targets. (A) Venn diagram displaying the intersect between genes identiﬁed as being
differentially regulated by microarray analysis following BRCA1 depletion with binding regions located in the promoters of the corresponding genes
bound by BRCA1 from ChIP-chip analysis. (B) Heat map from two-way hierarchical clustering analysis based on the 65 intersect transcripts for
control and BRCA1 siRNA treated cells. (C) Histogram demonstrating functional categories of direct BRCA1 target genes as analysed by DAVID.
(D) qRT–PCR of BRCA1 ChIP assays conﬁrming BRCA1 recruitment to promoters of direct BRCA1 targets. Amounts of immunoprecipitated
DNA was normalized to inputs and reported relative to the amount obtained at a non-speciﬁc control region. (E) qRT–PCR conﬁrming regulation
of target genes following siRNA inhibition of BRCA1 with two speciﬁc oligos (II and III) when compared to scrambled control, analysis of mRNA
levels for each target was normalized to b-actin mRNA. Statistically signiﬁcant differences were determined using Student’s t-test; *P<0.05;
**P<0.01; ***P<0.001.
Nucleic Acids Research, 2011,Vol.39, No. 22 9541analysis (using the genes common to both the BrDSA and
ChIP-chip array as a background gene list). DAVID
(Database for Annotation, Visualisation and Integrated
Discovery) analysis revealed that 12 of the 44 genes
(27%) were involved in transcriptional regulation
(Figure 3C). Therefore, this suggests that a major
function of BRCA1 is the regulation of additional TFs,
and may explain the large number of indirect targets
identiﬁed through the microarray screen.
As the overlap between the BrDSA and the ChIP-chip
array datasets is relatively small, it is possible that this
overlap may have occurred by chance ( 
2=4.63, 1 df,
P=0.031, z-score= 0.7170, P=0.2367). Therefore, in
order to conﬁrm that genes identiﬁed were indeed direct
transcriptional targets of BRCA1, we performed ChIP
and qRT–PCR analysis on a randomly selected panel of
14 ( 30%) of the genes identiﬁed as well as the ChIP
validation genes ESR1 and S100A7. ChIP analysis
demonstrated that BRCA1 was bound to the promoter
region of all 16 genes tested. In addition, all of the genes
identiﬁed were differentially regulated upon BRCA1 de-
pletion in agreement with previously published data and
data derived from the BrDSA expression array, suggesting
that the methods used to identify the direct BRCA1 tran-
scriptional targets were robust (Figure 3D and E,
Supplementary Figure S7) (23,29).
Comparison of BRCA1 ChIP-chip data with gene
expression proﬁles generated following cellular stress
As mentioned above, a surprising ﬁnding of this study was
that, although BRCA1 was bound to the promoters of
over 600 genes, only a subset displayed differential gene
expression by microarray analysis following loss of
BRCA1. We postulated that BRCA1 may be bound to
these promoters primed to regulate transcription in
response to BRCA1 responsive stimuli such as DNA
damage or spindle poisons. In order to test this hypoth-
esis, we compared our list of BRCA1 bound promoters to
genes regulated in response to ionizing radiation (31),
etoposide (29) or paclitaxel (32) (fold-change  1.7,
P 0.05) from publicly available microarray expression
data (Figure 4A and Supplementary Figure S8). This
analysis revealed that different subsets of BRCA1 bound
promoters were activated/repressed depending on the
nature of the stimuli. For example, of the 36 genes that
were identiﬁed as being BRCA1 promoter bound and dif-
ferentially expressed following etoposide treatment, only a
single gene was also found in the corresponding overlap
from unperturbed cells (Figure 4B). This data is consistent
with the hypothesis that BRCA1 is bound to many pro-
moters in a non-functional complex that gets activated in
response to stimuli such as etoposide treatment.
In order to conﬁrm the in-silico data, we validated the
expression of a subset of the BRCA1 promoter bound
genes that were differentially regulated following etopo-
side treatment by qRT–PCR. Analysis revealed that
BRCA1 functions to both repress and induce gene expres-
sion following etoposide treatment. For example,
etoposide induced activation of CCL4L2 is almost com-
pletely abrogated following siRNA-mediated inhibition of
endogenous BRCA1 (Figure 4C). Conversely, inhibition
of endogenous BRCA1 results in a marked increase
in etoposide-mediated induction of PDE4DIP, suggesting
that BRCA1 functions to maintain repression of
PDE4DIP following etoposide treatment. We also
examined the protein expression of a subset of these
genes and conﬁrmed that BRCA1 depletion by siRNA
exacerbated etoposide-induced induction (Figure 4D).
We also assessed, using ChIP, if BRCA1 promoter occu-
pancy is altered in response to etoposide treatment at a
subset of these promoters (Figure 4E). In support of a
model where BRCA1 is bound to promoters in both the
absence and presence of DNA damage, BRCA1 occu-
pancy of these eight representative promoters is unaltered
after etoposide treatment.
Identiﬁcation of novel BRCA1 interacting TFs
Finally, we sought to identify known and novel TFs that
might be responsible for recruitment of BRCA1 by
carrying out TF motif analysis on the BRCA1 bound
regions of the 44 direct target genes identiﬁed in unper-
turbed cells. Using CEAS we ranked each consensus TF
binding motif based on how many times the sequence
appears within the given promoter, and on the signiﬁcance
of enrichment of the motif within that promoter compared
with the entire human genome. This ranking was per-
formed for all consensus TF motifs identiﬁed within
BRCA1 bound regions on each target promoter. The
‘hit’ score for each TF motif was then weighted according
to its rank within each individual promoter. We then
plotted the combined hit score for each consensus TF
motif to produce a graph representing the most highly
ranked consensus TF motif across all of the direct
BRCA1 target genes (Figure 5A). This analysis identiﬁed
known BRCA1 interacting TFs such as STAT5A (33),
TBP (4), CBP, CREB (34) and E2F (27). In addition, a
number of novel putative BRCA1 interacting TFs were
identiﬁed such as ZF5, AP2-a and Pax-2. BRCA1
co-immunoprecipitation experiments conﬁrmed inter-
actions between E2F-1 and BRCA1 but also interactions
between BRCA1 and ZF5, AP2-a and Pax-2 (Figure 5B).
Pax-4, also identiﬁed as a possible interacting TF in
our analysis did not appear to interact with BRCA1.
Unfortunately, although the Churchill (Churc1) TF
ranked extremely highly in our analysis, antibodies were
not available to this protein and thus, we could not test its
ability to interact with BRCA1. In order to determine if
these BRCA1 interacting TFs are indeed responsible for
recruiting BRCA1 to speciﬁc promoters, we examined the
ability of the two most highly ranked TFs from our
search, AP2-a and ZF5 to recruit BRCA1 to the NME1
and PPM1D promoters, respectively (these pro-
moters were among those identiﬁed using CEAS to
contain AP2-a and ZF5 binding sites) (Figure 5C).
ChIP–qRT–PCR analysis revealed both AP2-a and
BRCA1 bind the same region within the NME1
promoter in control cells (siGFP), however,
siRNA-mediated depletion of AP2-a results in loss of
BRCA1 binding to the NME1 promoter. Similarly, both
BRCA1 and ZF5 bind the same region within the PPM1D
9542 Nucleic Acids Research, 2011,Vol.39, No. 22Figure 4. Comparison of BRCA1 ChIP-chip data with gene-expression proﬁles generated following cellular stress. (A) Venn diagrams displaying the
intersection between transcripts identiﬁed as being differentially regulated following IR, etoposide and paclitaxel treatment with transcripts located in
the promoters of the corresponding genes bound by BRCA1 from ChIP-chip analysis. (B) Venn diagram displaying the intersect between direct
BRCA1 regulated targets in unperturbed cells with direct BRCA1 targets identiﬁed following etoposide treatment. (C) qRT–PCR showing fold
change of expression between control and BRCA1-depleted cells upon etoposide treatment (5 10
 6 M). The statistical signiﬁcance of fold change
upon treatment was analysed using the Student’s t-test; *P<0.05; **P<0.01; ***P<0.001. (D) Western Blot analysis demonstrating the loss of
etoposide induction on a panel of BRCA1 targets following siRNA-mediated inhibition of endogenous BRCA1 in HEK 293 cells. g-tubulin was used
as a loading control. (E) qRT–PCR of BRCA1 ChIP assays from unperterbed cells and etoposide treated (5 10
 6 M) cells demonstrating that
BRCA1 promoter occupancy at these promoters is unchanged in response to DNA damage. Amounts of immunoprecipitated DNA were normalized
to inputs and reported relative to the amount obtained at a non-speciﬁc control region.
Nucleic Acids Research, 2011,Vol.39, No. 22 9543Figure 5. Identiﬁcation of novel BRCA1 interacting TFs. (A) Histogram demonstrating signiﬁcance of consensus TF binding motifs analysed by
CEAS within the peak coordinates from the ﬁnal 44 BRCA1 bound genes. Each TF identiﬁed was ranked on ‘hits’ per promoter and fold change.
The greater the value, the more signiﬁcant that TF is within the target promoters. (B) Co-immunoprecipitation demonstrating the association of
endogenous BRCA1 with a panel of TFs in HEK 293 cells. (C) qRT–PCR of ChIP assay from cells treated with or without AP2-a-speciﬁc siRNA on
the promoter of NME1,o r( D) cells treated with or without ZF5-speciﬁc siRNA on the promoter of PPM1D, demonstrating that BRCA1 promoter
occupancy is reduced in response to siRNA treatment. Amounts of immunoprecipitated DNA were normalized to inputs and reported relative to the
amount obtained at a non-speciﬁc control region. The statistical signiﬁcance of fold change upon siRNA treatment was analysed using the Student’s
t-test; *P<0.05; **P<0.01; ***P<0.001.
9544 Nucleic Acids Research, 2011,Vol.39, No. 22promoter; however, depletion of ZF5 results in loss of
BRCA1 binding. These data suggest that both AP2-a
and ZF5 are indeed functionally relevant BRCA1 inter-
acting TFs, and supports a model, whereby novel BRCA1
interacting TFs mediate the recruitment/binding of
BRCA1 to target gene promoters.
Discussion
This study aimed to investigate the role of BRCA1 in
transcriptional regulation on a genomic scale by combin-
ing ChIP-chip and microarray based approaches. The
overlap of the ChIP-chip and microarray data revealed a
number of surprising ﬁndings. In the ﬁrst instance, it
indicated that of the 1294 differentially expressed genes
identiﬁed by microarray, only 44 were identiﬁed as
having BRCA1 bound at the promoter by ChIP-chip
analysis. This would suggest that at least in unperturbed
cells, the majority of differentially expressed genes identi-
ﬁed by microarray represent indirect BRCA1 transcrip-
tional targets. Gene ontology analysis revealed that
 30% of the direct BRCA1 targets identiﬁed were TFs
providing a potential explanation for the large number
of differentially expressed genes identiﬁed. Intriguingly,
many of these TFs such as FOXM1 and TIMELESS,
transcriptionally regulate genes tightly linked with
BRCA1 associated pathways. FOXM1 regulates the
G2-M cell-cycle checkpoint through transcriptional regu-
lation of a number of genes required for mitotic progres-
sion. Additionally, FOXM1 induces the expression of a
number of DNA repair genes and modulates cellular sen-
sitivity to cisplatin and paclitaxel, all functions associated
with BRCA1 (28,35,36). It is also likely that loss of
BRCA1 expression may lead to transcriptional regulation
through other more indirect mechanisms that are act-
ivated in response to BRCA1 regulated DNA damage
repair pathways. Finally, it is possible that the stringent
criteria we used to identify BRCA1 bound promoters may
have lead us to overlook some true BRCA1 bound
regions. Indeed, we compared the 890 BRCA1 bound
peaks identiﬁed in this study to a list of 29 BRCA1
bound promoters identiﬁed in the literature
(Supplementary Figure S9). Of this list, 17 gene promoters
(56%) were identiﬁed in at least one of the three BRCA1
ChIP-chip experiments. The lack of complete overlap of
our list of BRCA1 bound promoters with previously pub-
lished data is likely due to a number of factors. Among
these is the disparity in sensitivity between ChIP array
hybridization experiments versus ChIP-quantitative and
ChIP-semi-quantitative PCR used in these studies.
Additionally, the stringency used in this study reduced
the number of BRCA1 bound regions identiﬁed,
thereby, increasing the chance of missing true; albeit
weak BRCA1 binding sites (37–39).
The other surprising observation from this study was
the ﬁnding that the majority of BRCA1 promoter bound
genes did not display transcriptional deregulation follow-
ing BRCA1 depletion. This suggested that BRCA1 re-
cruitment to these gene promoters was non-speciﬁc or
that BRCA1 bound promoter complexes were primed to
respond to additional external stimuli. To test this hypoth-
esis, we compared the ChIP-chip data with additional,
publicly available, gene expression proﬁles generated, fol-
lowing treatment of cells with IR (Ionising Radiation),
etoposide or paclitaxel. Overlapping of the data revealed
that different subsets of BRCA1 promoter bound genes
were differentially expressed following the different types
of cellular stress. Moreover, comparison of the BRCA1
bound gene promoters regulated in response to IR with
those regulated in response to etoposide revealed that 7
BRCA1 bound promoters, ABCA1, MMP3, PDE4DIP,
STAT1, RARRES1, TFF1 and USP32 are commonly
regulated in response to IR and etoposide treatment, sug-
gesting that transcriptional regulation of these genes may
represent a common BRCA1-mediated response to DNA
damage. In contrast, comparing the BRCA1 bound gene
promoters commonly regulated in response to IR and
etoposide with those regulated in response to paclitaxel
(a mitotic spindle poison) revealed only a single gene,
STAT1 commonly regulated in response to these agents.
This is likely a reﬂection of the generalized stress response
pathways activated by STAT1. Furthermore, comparison
of the direct BRCA1 target genes identiﬁed in unperturbed
cells with BRCA1 promoter bound genes transcriptionally
regulated in cells treated with etoposide, revealed only a
single common transcript, suggesting that BRCA1 regu-
lates different subsets of genes in unperturbed cells and in
response to different stimuli. Taken together, this data sup-
ports the hypothesis that BRCA1 is part of an early
response transcriptional complex primed to respond dif-
ferentially to a variety of different stimuli, such as
genotoxic insult or mitotic spindle arrest.
We next demonstrated that a panel of the BRCA1
bound, etoposide regulated genes were altered by
BRCA1 depletion in etoposide treated cells, again suggest-
ing that BRCA1 regulates these genes in response to
genotoxic stress. Importantly, BRCA1 binding to the pro-
moters of these genes was not altered in response to
etoposide treatment, suggesting that transcriptional regu-
lation of these genes through BRCA1 is not regulated by
alterations in BRCA1 promoter occupancy.
The mechanism through which BRCA1 promoter
bound complexes are regulated in response to stimuli
such as DNA damage and spindle checkpoint arrest re-
mains unclear, however, it is likely to be through post-
translational modiﬁcation of BRCA1. Indeed, BRCA1 is
phosphorylated by the ATM and ATR (ATM and Rad3
related kinase) kinases at a number of serine residues fol-
lowing etoposide and IR-mediated DNA damage, and by
Chk2 in response to spindle poisons such paclitaxel
(40,41). In addition, given the large number of different
BRCA1 containing protein complexes formed in response
to DNA damage, it is possible that phosphorylation of
BRCA1 may regulate it’s ability to form different tran-
scriptional at BRCA1 bound promoters. It is also unclear
how different stimuli impact on BRCA1s ability to
transactivate or repress various genes. For example,
BRCA1, in complex with ZBRK1 and CtIP TFs represses
the expression of growth arrest and DNA damage gene
GADD45a in unperturbed cells. Meanwhile, a separate
complex, consisting of BRCA1 and NF-YA recruited by
Nucleic Acids Research, 2011,Vol.39, No. 22 9545Oct-1, is responsible for GADD45a-mediated activation
in response to DNA damage (42,43). Exactly what role
BRCA1 plays in these different complexes remains
unknown, however, the ﬁnding that BRCA1 is required
for both the ZBRK1-mediated repression of GADD45a,
as well as, the Oct-1-mediated activation of this gene,
suggests that perhaps BRCA1 may facilitate some sort
of switching mechanism in response to DNA damage. It
is possible that BRCA1 provides a scaffolding-like
function on these promoters functioning as a substrate
for the recruitment of co-activator or co-repressor
proteins upon cellular stress, which is potentially regulated
by BRCA1 phosphorylation. This is analogous to the
roles played by Hot1 and Smp1 proteins in
Saccharomyces Cerevisiae, facilitating MAP kinase
(Mitogen-activated protein kinase) signalling induced
transcription previously (44).
Since little is known about BRCA1 promoter binding
on a genomic scale, we analysed the speciﬁc regions bound
by BRCA1 in the 44 direct BRCA1 target genes identiﬁed
in unperturbed cells. CEAS analysis revealed that BRCA1
preferentially bound within the proximal promoter region
consistent with a role in the direct regulation of these tran-
scripts. We also attempted to determine if any common
conserved BRCA1 binding motif existed within bound
regions. We did not identify any conserved sequence
across BRCA1 binding regions including the previously
reported BRCA1 consensus binding site, TTC(G/
T)GTTG (45). This suggested that there is no in vivo
BRCA1 consensus binding motif and that it is probable
that, BRCA1 interacts with promoters via interactions
with multiple TFs. To identify potential TFs that may
be responsible for BRCA1 recruitment, we identiﬁed
possible consensus binding motifs within the promoters
of the 44 genes differentially expressed following
BRCA1 depletion which were also promoter bound by
BRCA1. This identiﬁed a number of known BRCA1 inter-
acting TFs such as STAT5A (33), TBP (4), CBP, CREB
(34) and E2F (27) which have all been demonstrated to
alter the transcriptional activity of BRCA1. This also
identiﬁed a number of novel putative BRCA1 interacting
TFs such as ZF5, AP2-a, Pax-2 and Churc1 which, with
the exception of Churc1, we conﬁrmed as BRCA1
interactors. We conﬁrmed that both AP2-a and ZF5 are
required for BRCA1 promoter binding at target gene pro-
moters, suggesting that many of the novel BRCA1 inter-
acting TFs identiﬁed are also likely required for BRCA1
binding at speciﬁc target gene promoters. AP2-a, ZF5 and
Pax-2, all function in the regulation of distinct transcrip-
tional programs. ZF5 is a kruppel-type TF which has been
shown to regulate the expression of the fragile-X causative
gene FMR1 (46). In addition, binding sites for ZF5 are
enriched in the genetic promoters of clock-regulated genes,
as have binding sites for the known BRCA1 interacting
TFs; E2F, AP-1 and NF-Y, SP1 and Oct-1 (14,15,47).
ZF5 binding sites are also enriched in the promoters of
Hermansky–Pudlak syndrome genes HPS3, HPS5 and
HPS6 (48); interestingly, this study also found enrichment
of Churc1 binding sites within the promoters of these
genes. Taken together, this suggests that BRCA1,
Churc1, ZF5 and the other BRCA1 interacting TFs
mentioned above may exist as a single and/or multiple
complex(es) involved in the transcriptional regulation of
various genes. AP2-a is involved in the transcriptional
regulation of many genes such as those involved in regu-
lation of the G2-M checkpoint, including Cyclin-B, and
has been reported to function as a co-repressor for
Myc-activated genes (49,50). Consistent with this,
BRCA1 is thought to regulate the G2-M checkpoint,
in-part, by repressing Cyclin-B (51). In addition, we have
previously shown that BRCA1 and c-Myc function
together in a transcriptional repression complex (29). In
contrast, Pax-2 is predominantly associated with the tran-
scriptional regulation of developmental genes involved in
many different pathways such as hedgehog signalling.
This study has identiﬁed a number of interesting
ﬁndings regarding the role played by BRCA1 in transcrip-
tional regulation at a genome-wide level. It is clear that
although deregulation of BRCA1 has a profound impact
on transcriptional regulation, much of this is indirect. This
study indicates that BRCA1 resides on many promoters in
an inactive complex that is primed for response to various
stimuli such as DNA damage and mitotic spindle poisons.
Given the differential phosphorylation patterns of
BRCA1 in response to various DNA damaging agents
and mitotic spindle poisons, it is possible that BRCA1
facilitates the ﬁne-tuning of transcriptional activation
and/or repression in response to different external
stimuli, through phosphorylation-mediated assembly of
various transcriptional complexes.
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